ABSTRACT
There is an agreement among rheumatologists that in the biggest part of RA patients the fi rst treatment approach should include synthetic DMARDs, since a signifi cant proportion of patients can reach a state of very low disease activity or remission (Figs. 2-4) (Smolen et al. 2010). Moreover, since any delay in the start of DMARD treatment in RA patients may lead to a worse outcome in comparison with an early start of treatment, a DMARD should be started as soon as a diagnosis of RA has been made.
